As of the most recent data (June 2026), 4166.TWO shows a receivables of $290M. That compares with $250M in the prior-year period — up 16.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4166.TWO's receivables is now $290M (was $250M) — a 16.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Orient Pharma , Ltd. is outperforming or lagging.

Tracking 4166.TWO's receivables over time shows whether Orient Pharma , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $290M That compares with $250M in the prior-year period — up 16.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Orient Pharma , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $290M) with ownership activity and broader fundamentals.